AXIOS August 16, 2023
One year after President Biden signed the Inflation Reduction Act, the future of the law’s signature drug pricing policy — Medicare negotiations — is up in the air.
Why it matters: A barrage of lawsuits from drugmakers and allied groups are seeking to overturn provisions enabling Medicare to negotiate drug prices, just as the Biden administration is preparing to announce the first set of drugs subject to the new policy. While the fate of Medicare negotiations is uncertain, the political terms the IRA set will be enshrined in future health policy debates, said experts across the political spectrum.
What they’re saying: Just passing Medicare drug negotiations, an idea that Democrats pushed for almost 20 years against fierce pharma resistance, signals...
Today's Sponsors
Today's Sponsor